Emerging Pharmaceutical Clusters Attracting FDI Inflows in Russia
The combined contribution of various factors such as increasing support from the government, rise in the expenditure on healthcare, and growth in the investments made by the private players will result in a RUB 1.5 Trillion pharmaceutical market in Russia by 2017. Similar to earlier years, the commercial drugs segment was estimated to have occupied the largest market share in 2012. Besides, the state drug segment is continuously declining and losing its share to the commercial segment.
View full press release